The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors
Open accessThe DOI matches its Crossref record; 79 of the 83 references it cites were found in a registry or an index; 82 of the 155 sources its claims cite were checked for support.
Abstract
Testicular germ cell tumors (TGCTs) are cancers with very good prognosis, even in the metastatic setting, with high curative potential mainly attributed to the introduction of cisplatin-based chemotherapy. However, approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses. Therefore, there is an unmet need for novel therapeutic agents with improved efficacy and minimal long-term side effects. Recent advances in the development of immunotherapeutic agents, particularly immune checkpoint inhibitors (ICIs), have offered an opportunity to test their activity in various tumor types, including GCTs. This review aims to analyze the immune microenvironment of these tumors and present the most recently available data from studies that have tested immunotherapeutic agents against GCTs. The majority of the available knowledge derives from case reports or small cohort studies, particularly those involving ICIs of the PD-1/PD-L1 axis alone or in combination with anti-CTLA-4 monoclonal antibodies. Other immunotherapeutic targeted approaches, including antibody-drug conjugates, antibody prodrugs, vaccines, tyrosine kinase inhibitors, chimeric antigen receptor (CAR) T-cell therapy, have biological rationales and have shown preliminary activity or are currently being tested. Growing evidence on these and other approaches will assist in broadening the currently limited treatment armamentarium against platinum-refractory TGCTs.
Overview
CoChat Summary
## TL;DR
This is a systematic review of the immune microenvironment of testicular germ cell tumors (TGCTs) and the very limited clinical evidence for immunotherapy in platinum-refractory disease. The paper concludes that current immune checkpoint inhibitor results are mostly disappointing, but biomarker-driven trials and newer approaches such as antibody-drug conjugates, prodrugs, vaccines, and CAR-T cells may expand treatment options.
## Key findings
- Approximately 15% of patients with TGCTs develop platinum-refractory disease; the authors also state that one-fifth of patients with advanced TGCTs develop platinum-refractory disease.
- In a case series of 7 platinum-refractory patients treated with nivolumab or pembrolizumab, 4 died after a single dose, while 2 had long-term tumor response associated with high PD-L1 expression.
- In a phase II study of 12 cisplatin-refractory patients treated with pembrolizumab, there were no partial or complete responses; 2/12 had stable disease lasting 28 and 19 weeks.
- In a phase II study of 8 patients treated with avelumab, all progressed within 2.6 months; median PFS was 0.9 months and median OS was 2.7 months. A durvalumab ± tremelimumab trial enrolled 22 patients; the combination arm had 1 partial response and 1 stable disease with serologic improvement.
- For brentuximab vedotin, one study of 7 CD30-overexpressing patients reported 2 objective responses (1 complete, 1 partial), but a later 18-patient phase II study found no partial or complete responses; median PFS was 1.2 months in CD30-positive patients and 1.4 months in CD30-negative patients.
## Methods
- Design: Systematic review conducted according to PRISMA guidelines; the study was not registered.
- Data/sample: Literature search in PubMed and Web of Science using terms related to TGCTs, immunotherapy, PD-L1, CTLA-4, platinum-resistant, and platinum-refractory disease.
- Main analysis: Narrative synthesis of the immune landscape of TGCTs and the preclinical/clinical evidence for immunotherapeutic strategies, with emphasis on published case reports, small cohorts, and early-phase trials.
## Limitations
- The paper explicitly states that randomized data are largely absent in advanced TGCTs, and that the best available evidence comes from small cohort studies and case reports.
- The authors note that the review was not registered.
- Evidence for many emerging approaches is described as preliminary or based on biological rationale rather than definitive clinical proof (evident from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
74 Valid · 4 Not valid · 55 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Median overall survival (OS) was 2.5 and 5 months in the CD30-positive and CD30-negative groups, respectively [56].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 5. Immunotherapy in TGCTs > 5.2. Anti-CD30 Antibody-Drug Conjugate Therapy To identify novel therapeutic agents for patients with cisplatin-refractory disease and following the poor results of anti-PD-1/PD-L1 inhibitors in the management of these patients, the antibody-drug conjugate brentuximab vedotin was tested in clinical trials. This conjugate is composed of a chimeric antibody that is covalently linked to the cell-surface antigen CD30, and it is combined with the cytotoxic anti-tubulin agent monomethylauristatin E. In a phase II study, seven patients with multiple relapses or cisplatin-refractory disease and CD30 overexpression were enrolled. The patients received treatment with brentuximab vedotin, initially administered at doses of 1.8 or 2.4 mg/kg every 3 weeks. Assessment of treatment response was conducted after cycles 2 and 4, and subsequently after every four cycles. Two patients had an objective response to the treatment. One patient exhibited a sustained complete response while the other had a partial response [54]. In a separate study, a group of nine patients with CD30-positive GCTs were treated with brentuximab vedotin. Among them, 11.1% of the patients had progression-free survival (PFS) of 3 months, while 85.7% of the patients achieved 6-month overall survival (OS)) [55]. Recently, a phase II one arm study enrolling 18 patients investigated brentuximab vedotin in CD30-positive and CD30-negative/unknown patients [56]. No partial or complete responses were observed. Out of the 18 patients who participated in the study, six of them had stable disease. Among the six patients with stable disease, five had elevated levels of AFP or hCG at the beginning of the trial. However, all five patients had an initial decline of more than 50% in AFP or hCG levels that started to rise again at the time of disease progression. Two of the six patients belonged to the CD30 positive group, while the remaining four were in the CD30 negative group. Out of the 12 remaining patients, 10 experienced progressive disease as their best response. Two patients, one from the CD30 positive group and one from the CD30 negative group died before the first disease re-evaluation. Median progression-free survival (PFS) in the CD30-positive group was 1.2 months and 1.4 months in the CD30-negative group. Median overall survival (OS) was 2.5 and 5 months in the CD30-positive and CD30-negative groups, respectively [56].
What the sources say
- Disputedcites [56] Ashkar R. Feldman D.R. Adra N. Zaid M.A. Funt S.A. Althouse S.K. Perkins S.M. Snow C.I. Lazzara K.M. Sego L.M. Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Investig. New Drugs 2021 39 1656 1663 10.1007/s10637-021-01134-1 34031784 PMC9534326 sourceExperimental — accuracy not yet measured
The Efficacy section reports median OS of 5.9 months in the CD30-negative cohort, not 5 months. The citing sentence's 2.5-month figure for the CD30-positive cohort matches the paper, but the claim about the CD30-negative cohort does not. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A recent immunohistochemical analysis of seminoma samples revealed the overexpression of several immune checkpoint receptors in the cancerous cells.”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 5. Immunotherapy in TGCTs > 5.3. Emerging Immunotherapeutic Targets
What the sources say
- Disputedcites [57] Hinsch A. Blessin N.C. Simon R. Kluth M. Fischer K. Hube-Magg C. Li W. Makrypidi-Fraune G. Wellge B. Mandelkow T. Expression of the Immune Checkpoint Receptor TIGIT in Seminoma Oncol. Lett. 2019 18 1497 1502 10.3892/ol.2019.10428 31423216 PMC6607271 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report TIGIT and PD-1 staining in immune cells within all 78 seminomas, not overexpression in the cancerous cells. The Introduction likewise says the study examined these receptors on lymphocytes. The claim assigns the finding to the wrong cell type. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 3. The Immune Landscape of TGCTs Testicular tissue is characterized as an immune-privileged site. In order to promote spermatogenesis and avoid autoimmune attack against germ cells, immune suppression must take place. However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15]. In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19]. Immune response against malignant cells is mediated by immune cells and cytokines. Various studies have revealed different immunological patterns in patients with germ cell neoplasia (GCN) or in situ germ cell neoplasia (GCNIS) compared to men with normal testicular tissue or inflammatory lesions related to hypospermatogenesis. In patients with testicular tumors, B-cells and dendritic cells are abundant in TME, while T cells are present in both malignant and normal tissue. In addition to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, anti-inflammatory cytokines (TGF-β1), Th1-driven cytokines (IL-2 and IFN-γ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20]. Moreover, recent studies have confirmed the significant effect of the interaction between malignant cells and TME on the modulation of the immune microenvironment. The crosstalk between malignant cells and TME leads to the overexpression of extracellular matrix proteins such as collagen I/IV and fibronectin, resulting in the elevated adhesive and migratory capacity of GCT cells. Most importantly, cisplatin sensitivity was found to be decreased in these patients [21]. Based on these observations of the alterations of the immune microenvironment of TGCTs and the availability of ICIs as the therapeutic option in other malignancies, a number of studies focused on evaluating novel immune biomarkers that could be differentially expressed between tumor and normal counterparts. The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22]. While PD-L1 expression is absent in normal tissue and GCNIS lesions, it is upregulated in GCN lesions [23]. PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24]. Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23]. With regard to histological subtypes, PD-L1 overexpression was found to be most pronounced in patients with choriocarcinomas, while decreased in embryonal carcinoma, teratoma and yolk sack tumors, with the lowest expression observed in seminomas [24]. Besides the differential expression of immune markers which is fundamental to establishing a potential specific effect of targeted therapies, identifying the prognostic or/and predictive surrogate markers in the trajectory of testicular tumors treated with immunotherapy is important. Indeed, expression of the programmed death receptor axis (PD-1/PD-L1) was found to have prognostic value in TGCTs, being associated with progression-free survival (PFS) and overall survival (OS). High PD-L1 expression is a harbinger of poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers and the presence non-pulmonary visceral metastases, whereas low PD-L1 expression is associated with longer PFS and OS [24]. Besides PD-L1 overexpression in testicular tumor cells, microarray-based analyses revealed the abundance of PD-1-positive tumor infiltrating T cells, also known as TILs. Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25]. TILs are an important TME component, and their activity depends on immune checkpoint regulators such as V-domain Ig suppressor of T cell activation (VISTA) and PD-1/PD-L1 axis. In this context, a study by Chovanec et al. revealed that patients with GCN and abundant PD-L1 (+) TILs in the TME had significantly better outcomes than patients with lower expression [26]. The notion that the ability of testicular cancer cells to escape the immune system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26]. Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer. They used multiplexed fluorescence immunohistochemistry (FIHC) to analyze T-cell subsets, immune checkpoints, and targeted gene expression profiling, aiming to comprehensively understand the composition of immune infiltrates. Their findings revealed the presence and favorable prognostic utility of activated CD3+ T-cell infiltration, PD-L1 overexpression, and increased spatial interaction between PD-1 and PD-L1 in seminomas [27]. Conversely, non-seminomas exhibited elevated gene signatures associated with neutrophils and macrophages. Advanced stages of the disease, regardless of the histological tumor type, were characterized by reduced T-cell and NK-cell signatures, while Treg, neutrophil, mast cell, and macrophage signatures were elevated in these cases [27]. Combined PD-L1 and VISTA overexpression is particularly found in patients with choriocarcinoma components. Notably, 37.22% of patients exhibited high VISTA expression, while 49.44% showed high PD-L1 expression in a recent study. Conversely, a small percentage of seminoma patients (7.2%) had complete absence of PD-L1, as did 3.6% of men with non-seminomatous embryonal (NSE) tumors. Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28]. Low VISTA expression in tumor-associated immune cells was associated with shorter progression-free and overall survival [28]. Besides PD-L1 overexpression in GCN, the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is also highly expressed in TILs regardless of the histological TGCT type, while the expression of CTLA-4 in tumor cells is predominantly found in yolk sack tumors, choriocarcinomas, and teratomas [27]. When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29]. Additional studies have examined the expression of PD-L1 and CTLA-4 in tumor-associated macrophages (TAMs). In cases where tumor cells do not express PD-L1, there is often an overexpression of PD-L1 in TAMs. In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30]. Regarding prognosis, the absence of PD-L1 positivity in immune cells is associated with worse relapse-free survival (RFS), while overexpression of CTLA-4 was correlated with good prognostic features such as the absence of lymphovascular invasion and lower pT and N stages [29]. Accumulating evidence suggests that not only the tumoral immune cell infiltration but also the proportion of lymphocytes relative to other immune cell types in the peripheral blood may be associated with the prognosis for these patients. Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35]. SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33]. However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34]. Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32]. The best prognosis is seen in patients with a high expression of PD-L1 in TILs and a low SII (SII < 1003) with a 5-year PFS and OS of 100%, while the worst prognosis is experienced by patients with a low expression of PDL1 in TILs and high SII (SII ≥ 1003), with a 5-year PFS and OS of 70% and 70%, respectively. Patients with combinations of high/high or low/low SII and PD-L1 in TILs have an intermediate prognosis [32].
What the sources say
- Not checked — no full text of the sourcecites [16] Milia-Argeiti E. Mourah S. Vallée B. Huet E. Karamanos N.K. Theocharis A.D. Menashi S. EMMPRIN/CD147-Encriched Membrane Vesicles Released from Malignant Human Testicular Germ Cells Increase MMP Production through Tumor–Stroma Interaction Biochim. Et Biophys. Acta (BBA)-General. Subj. 2014 1840 2581 2588 10.1016/j.bbagen.2014.02.026 24608032 source
- Partly supportedcites [17] Kozlova N. Grossman J.E. Iwanicki M.P. Muranen T. The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers Trends Pharmacol. Sci. 2020 41 183 198 10.1016/j.tips.2020.01.001 32014341 PMC8812124 sourceExperimental — accuracy not yet measured
The “Immune cells and the TME” section describes how tumor-cell and stromal signals recruit immunosuppressive cells, supporting the general link between tumor–microenvironment interactions and disrupted immune responses. It does not establish that link specifically in TGCTs; the searches for TGCTs and testicular germ cell tumors found no such discussion in our copy. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [18] Anderson N.M. Simon M.C. The Tumor Microenvironment Curr. Biol. 2020 30 R921 R925 10.1016/j.cub.2020.06.081 32810447 PMC8194051 source
- Partly supportedcites [19] Müller M.R. Skowron M.A. Albers P. Nettersheim D. Molecular and Epigenetic Pathogenesis of Germ Cell Tumors Asian J. Urol. 2021 8 144 154 10.1016/j.ajur.2020.05.009 33996469 PMC8099689 sourceExperimental — accuracy not yet measured
The section “The influence of microenvironment on TGCT pathogenesis” (page unavailable) describes a pro-inflammatory milieu in GCNIS and seminoma and suggests that it may favor TGCT development. The Conclusion (page unavailable) also identifies immune cells and inflammatory signals in the TGCT microenvironment. Neither passage says that interactions between malignant cells and the microenvironment disrupt immune balance. (LLM, conf=0.83)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 3. The Immune Landscape of TGCTs Testicular tissue is characterized as an immune-privileged site. In order to promote spermatogenesis and avoid autoimmune attack against germ cells, immune suppression must take place. However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15]. In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19]. Immune response against malignant cells is mediated by immune cells and cytokines. Various studies have revealed different immunological patterns in patients with germ cell neoplasia (GCN) or in situ germ cell neoplasia (GCNIS) compared to men with normal testicular tissue or inflammatory lesions related to hypospermatogenesis. In patients with testicular tumors, B-cells and dendritic cells are abundant in TME, while T cells are present in both malignant and normal tissue. In addition to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, anti-inflammatory cytokines (TGF-β1), Th1-driven cytokines (IL-2 and IFN-γ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20]. Moreover, recent studies have confirmed the significant effect of the interaction between malignant cells and TME on the modulation of the immune microenvironment. The crosstalk between malignant cells and TME leads to the overexpression of extracellular matrix proteins such as collagen I/IV and fibronectin, resulting in the elevated adhesive and migratory capacity of GCT cells. Most importantly, cisplatin sensitivity was found to be decreased in these patients [21]. Based on these observations of the alterations of the immune microenvironment of TGCTs and the availability of ICIs as the therapeutic option in other malignancies, a number of studies focused on evaluating novel immune biomarkers that could be differentially expressed between tumor and normal counterparts. The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22]. While PD-L1 expression is absent in normal tissue and GCNIS lesions, it is upregulated in GCN lesions [23]. PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24]. Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23]. With regard to histological subtypes, PD-L1 overexpression was found to be most pronounced in patients with choriocarcinomas, while decreased in embryonal carcinoma, teratoma and yolk sack tumors, with the lowest expression observed in seminomas [24]. Besides the differential expression of immune markers which is fundamental to establishing a potential specific effect of targeted therapies, identifying the prognostic or/and predictive surrogate markers in the trajectory of testicular tumors treated with immunotherapy is important. Indeed, expression of the programmed death receptor axis (PD-1/PD-L1) was found to have prognostic value in TGCTs, being associated with progression-free survival (PFS) and overall survival (OS). High PD-L1 expression is a harbinger of poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers and the presence non-pulmonary visceral metastases, whereas low PD-L1 expression is associated with longer PFS and OS [24]. Besides PD-L1 overexpression in testicular tumor cells, microarray-based analyses revealed the abundance of PD-1-positive tumor infiltrating T cells, also known as TILs. Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25]. TILs are an important TME component, and their activity depends on immune checkpoint regulators such as V-domain Ig suppressor of T cell activation (VISTA) and PD-1/PD-L1 axis. In this context, a study by Chovanec et al. revealed that patients with GCN and abundant PD-L1 (+) TILs in the TME had significantly better outcomes than patients with lower expression [26]. The notion that the ability of testicular cancer cells to escape the immune system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26]. Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer. They used multiplexed fluorescence immunohistochemistry (FIHC) to analyze T-cell subsets, immune checkpoints, and targeted gene expression profiling, aiming to comprehensively understand the composition of immune infiltrates. Their findings revealed the presence and favorable prognostic utility of activated CD3+ T-cell infiltration, PD-L1 overexpression, and increased spatial interaction between PD-1 and PD-L1 in seminomas [27]. Conversely, non-seminomas exhibited elevated gene signatures associated with neutrophils and macrophages. Advanced stages of the disease, regardless of the histological tumor type, were characterized by reduced T-cell and NK-cell signatures, while Treg, neutrophil, mast cell, and macrophage signatures were elevated in these cases [27]. Combined PD-L1 and VISTA overexpression is particularly found in patients with choriocarcinoma components. Notably, 37.22% of patients exhibited high VISTA expression, while 49.44% showed high PD-L1 expression in a recent study. Conversely, a small percentage of seminoma patients (7.2%) had complete absence of PD-L1, as did 3.6% of men with non-seminomatous embryonal (NSE) tumors. Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28]. Low VISTA expression in tumor-associated immune cells was associated with shorter progression-free and overall survival [28]. Besides PD-L1 overexpression in GCN, the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is also highly expressed in TILs regardless of the histological TGCT type, while the expression of CTLA-4 in tumor cells is predominantly found in yolk sack tumors, choriocarcinomas, and teratomas [27]. When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29]. Additional studies have examined the expression of PD-L1 and CTLA-4 in tumor-associated macrophages (TAMs). In cases where tumor cells do not express PD-L1, there is often an overexpression of PD-L1 in TAMs. In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30]. Regarding prognosis, the absence of PD-L1 positivity in immune cells is associated with worse relapse-free survival (RFS), while overexpression of CTLA-4 was correlated with good prognostic features such as the absence of lymphovascular invasion and lower pT and N stages [29]. Accumulating evidence suggests that not only the tumoral immune cell infiltration but also the proportion of lymphocytes relative to other immune cell types in the peripheral blood may be associated with the prognosis for these patients. Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35]. SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33]. However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34]. Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32]. The best prognosis is seen in patients with a high expression of PD-L1 in TILs and a low SII (SII < 1003) with a 5-year PFS and OS of 100%, while the worst prognosis is experienced by patients with a low expression of PDL1 in TILs and high SII (SII ≥ 1003), with a 5-year PFS and OS of 70% and 70%, respectively. Patients with combinations of high/high or low/low SII and PD-L1 in TILs have an intermediate prognosis [32].
What the sources say
- Partly supportedcites [23] Fankhauser C.D. Curioni-Fontecedro A. Allmann V. Beyer J. Tischler V. Sulser T. Moch H. Bode P.K. Frequent PD-L1 Expression in Testicular Germ Cell Tumors Br. J. Cancer 2015 113 411 413 10.1038/bjc.2015.244 26171934 PMC4522642 sourceExperimental — accuracy not yet measured
The Results (page not available) report PD-L1 positivity of 53% in pT1, 66% in pT2, and 70% in pT3 tumors, matching the cited figures. They do not report that the differences between stages are statistically significant, so the claim of “significant overexpression” is unsupported. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34].”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > 3. The Immune Landscape of TGCTs Testicular tissue is characterized as an immune-privileged site. In order to promote spermatogenesis and avoid autoimmune attack against germ cells, immune suppression must take place. However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15]. In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16,17,18,19]. Immune response against malignant cells is mediated by immune cells and cytokines. Various studies have revealed different immunological patterns in patients with germ cell neoplasia (GCN) or in situ germ cell neoplasia (GCNIS) compared to men with normal testicular tissue or inflammatory lesions related to hypospermatogenesis. In patients with testicular tumors, B-cells and dendritic cells are abundant in TME, while T cells are present in both malignant and normal tissue. In addition to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNF-α, anti-inflammatory cytokines (TGF-β1), Th1-driven cytokines (IL-2 and IFN-γ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20]. Moreover, recent studies have confirmed the significant effect of the interaction between malignant cells and TME on the modulation of the immune microenvironment. The crosstalk between malignant cells and TME leads to the overexpression of extracellular matrix proteins such as collagen I/IV and fibronectin, resulting in the elevated adhesive and migratory capacity of GCT cells. Most importantly, cisplatin sensitivity was found to be decreased in these patients [21]. Based on these observations of the alterations of the immune microenvironment of TGCTs and the availability of ICIs as the therapeutic option in other malignancies, a number of studies focused on evaluating novel immune biomarkers that could be differentially expressed between tumor and normal counterparts. The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22]. While PD-L1 expression is absent in normal tissue and GCNIS lesions, it is upregulated in GCN lesions [23]. PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24]. Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23]. With regard to histological subtypes, PD-L1 overexpression was found to be most pronounced in patients with choriocarcinomas, while decreased in embryonal carcinoma, teratoma and yolk sack tumors, with the lowest expression observed in seminomas [24]. Besides the differential expression of immune markers which is fundamental to establishing a potential specific effect of targeted therapies, identifying the prognostic or/and predictive surrogate markers in the trajectory of testicular tumors treated with immunotherapy is important. Indeed, expression of the programmed death receptor axis (PD-1/PD-L1) was found to have prognostic value in TGCTs, being associated with progression-free survival (PFS) and overall survival (OS). High PD-L1 expression is a harbinger of poor prognostic features, including non-seminomatous histology, increased number of metastatic sites, high serum tumor markers and the presence non-pulmonary visceral metastases, whereas low PD-L1 expression is associated with longer PFS and OS [24]. Besides PD-L1 overexpression in testicular tumor cells, microarray-based analyses revealed the abundance of PD-1-positive tumor infiltrating T cells, also known as TILs. Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25]. TILs are an important TME component, and their activity depends on immune checkpoint regulators such as V-domain Ig suppressor of T cell activation (VISTA) and PD-1/PD-L1 axis. In this context, a study by Chovanec et al. revealed that patients with GCN and abundant PD-L1 (+) TILs in the TME had significantly better outcomes than patients with lower expression [26]. The notion that the ability of testicular cancer cells to escape the immune system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26]. Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer. They used multiplexed fluorescence immunohistochemistry (FIHC) to analyze T-cell subsets, immune checkpoints, and targeted gene expression profiling, aiming to comprehensively understand the composition of immune infiltrates. Their findings revealed the presence and favorable prognostic utility of activated CD3+ T-cell infiltration, PD-L1 overexpression, and increased spatial interaction between PD-1 and PD-L1 in seminomas [27]. Conversely, non-seminomas exhibited elevated gene signatures associated with neutrophils and macrophages. Advanced stages of the disease, regardless of the histological tumor type, were characterized by reduced T-cell and NK-cell signatures, while Treg, neutrophil, mast cell, and macrophage signatures were elevated in these cases [27]. Combined PD-L1 and VISTA overexpression is particularly found in patients with choriocarcinoma components. Notably, 37.22% of patients exhibited high VISTA expression, while 49.44% showed high PD-L1 expression in a recent study. Conversely, a small percentage of seminoma patients (7.2%) had complete absence of PD-L1, as did 3.6% of men with non-seminomatous embryonal (NSE) tumors. Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28]. Low VISTA expression in tumor-associated immune cells was associated with shorter progression-free and overall survival [28]. Besides PD-L1 overexpression in GCN, the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is also highly expressed in TILs regardless of the histological TGCT type, while the expression of CTLA-4 in tumor cells is predominantly found in yolk sack tumors, choriocarcinomas, and teratomas [27]. When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29]. Additional studies have examined the expression of PD-L1 and CTLA-4 in tumor-associated macrophages (TAMs). In cases where tumor cells do not express PD-L1, there is often an overexpression of PD-L1 in TAMs. In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30]. Regarding prognosis, the absence of PD-L1 positivity in immune cells is associated with worse relapse-free survival (RFS), while overexpression of CTLA-4 was correlated with good prognostic features such as the absence of lymphovascular invasion and lower pT and N stages [29]. Accumulating evidence suggests that not only the tumoral immune cell infiltration but also the proportion of lymphocytes relative to other immune cell types in the peripheral blood may be associated with the prognosis for these patients. Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31,32,33,34,35]. SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33]. However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34]. Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32]. The best prognosis is seen in patients with a high expression of PD-L1 in TILs and a low SII (SII < 1003) with a 5-year PFS and OS of 100%, while the worst prognosis is experienced by patients with a low expression of PDL1 in TILs and high SII (SII ≥ 1003), with a 5-year PFS and OS of 70% and 70%, respectively. Patients with combinations of high/high or low/low SII and PD-L1 in TILs have an intermediate prognosis [32].
What the sources say
- Supportedcites [34] Ribnikar D. Stukalin I. Bedard P.L. Hamilton R.J. Jewett M. Warde P. Chung P. Anson-Cartwright L. Templeton A.J. Amir E. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer Curr. Oncol. 2021 28 107 114 10.3390/curroncol28010014 33622996 PMC7816171 source
The Discussion (§4) states that elevated NLR was associated with adverse PFS and OS, but not independently of IGCCCG risk classification. The Conclusions (§5) repeat this finding for patients with metastatic germ-cell tumors receiving first-line chemotherapy. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
102 more claims · 54 with their cited sources checked
Create a free account to see all 146 claims and to verify the 20 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > Abstract > Simple Summary
“One-fifth of patients with advanced testicular germ cell tumors (TGCTs) develop platinum-refractory disease.”
§ The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors > Abstract
“However, approximately 15% of the patients develop platinum-refractory disease and suffer multiple relapses.”
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“This systematic review was conducted according to the criteria included in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13,14].”
MethodPage, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262 · cited 1×
“This systematic review was conducted according to the criteria included in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13,14].”
MethodAnderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 1×
“Additionally, it may assist in promoting cancer cell apoptosis and the proliferation of antigen-specific T cells, while simultaneously inducing apoptosis in T-regulatory cells [38].”
BackgroundTim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856 · cited 1×
“Furthermore, T-cell immunoglobulin and mucin domain-3 (TIM-3) have been identified as important immunoreceptors involved in T-cell exhaustion, leading to the inactivation of these cells [58].”
BackgroundThe testis in immune privilege
Fijak, M., & Meinhardt, A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00438.x · Cited by 483 · cited 1×
“However, this immune suppression has to be in balance with the activation of the immune response that aims to fight infection, trauma, cancer and conditions resulting in tissue damage [15].”
BackgroundTesticular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450 · cited 1×
“Testicular germ cell tumors (TGCTs) are the most common malignancy among men between 20 and 40 years of age, with a rising incidence [1].”
BackgroundCognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity
Smith, C. M., Wilson, N. S., Waithman, J., Villadangos, J. A., Carbone, F. R., Heath, W. R., & Belz, G. T. (2004) · Nature Immunology · doi:10.1038/ni1129 · Cited by 448 · cited 1×
“MDSCs and Tregs are characterized by an immune inhibitory potential, whereas differentiated dendritic cells support antigen presentation and play a pivotal role in initiating the adaptive immune response [44].”
BackgroundRajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Bellmunt, J., Powles, T., & Vogelzang, N. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.007 · Cited by 374 · cited 1×
“The immune checkpoint PD-L1 is one of the regulators of immune response to tumor cells, and the PD-1/PD-L1 pathway has an immunosuppressive effect that helps promote carcinogenesis [22].”
BackgroundImmune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes
Tsavaris, N., Kosmas, C., Vadiaka, M., Kanelopoulos, P., & Boulamatsis, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600347 · Cited by 343 · cited 1×
“Taxanes have also demonstrated the ability to boost the Th1 population, leading to the production of IFN-c and IL-2, which in turn further stimulate the proliferation and activity of cytotoxic T cells [41].”
BackgroundWan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295 · cited 1×
“Furthermore, cisplatin, etoposide, and paclitaxel can stimulate tumor cells to produce IFN-b, serving as a signaling molecule that orchestrates the expression of MHC class I molecules which are critical for antigen presentation [40].”
BackgroundChemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242 · cited 1×
“For example, chemotherapy can trigger the expression of co-stimulatory molecules such as CD80 on tumor cells while reducing the levels of immunosuppressive checkpoint molecules such as PD-L1 and PD-L2, as well as VTCN1 [37].”
BackgroundRegulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Le, D. T., & Jaffee, E. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3912 · Cited by 240 · cited 1×
“Notably, paclitaxel fosters the differentiation of myeloid-derived suppressor cells (MDSCs) into dendritic cells [42] while concurrently reducing the population of MDSCs and T-regulatory cells [43].”
TIM-3, a promising target for cancer immunotherapy
He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235 · cited 1×
“Consequently, combining PD-1 and TIM-3 blockade might offer improved outcomes in overcoming resistance to anti-PD-1 therapy [59].”
BackgroundAdra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196 · cited 2×
“However, it is worth noting that both of these patients exhibited ongoing increases in AFP levels despite radiographic stability, and their corresponding tumors lacked PD-L1 expression on immunochemical staining [50].”
BackgroundFrequent PD-L1 Expression in Testicular Germ Cell Tumors
Fankhauser, C. D., Curioni-Fontecedro, A., Allmann, V, Beyer, J., Tischler, V, Sulser, T., Moch, H., & Bode, P. K. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.244 · Cited by 174 · cited 2×
“Moreover, the expression of PD-L1 in these patients has been directly associated with tumor stage, with significant overexpression being reported in advanced pT stages (53% in pT1, 66% in pT2 and 70% in pT3) [23].”
BackgroundTu, L., Guan, R., Yang, H., Zhou, Y., Hong, W., Ma, L., Zhao, G., & Yu, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.32785 · Cited by 167 · cited 1×
“However, no significant differences in the expression of LAG-3 and TIM-3 were observed between TGCTs, ovarian cancer, and their corresponding normal adjacent tissues [61].”
BackgroundCierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv574 · Cited by 162 · cited 3×
“PD-L1 is overexpressed in patients with GCN (76% of seminomas and 89% of non-seminomas) compared to normal testicular tissue [24].”
BackgroundInfluentialMichels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158 · cited 1×
“Notably, paclitaxel fosters the differentiation of myeloid-derived suppressor cells (MDSCs) into dendritic cells [42] while concurrently reducing the population of MDSCs and T-regulatory cells [43].”
BackgroundSpecific Immune Cell and Cytokine Characteristics of Human Testicular Germ Cell Neoplasia
Klein, B., Haggeney, T., Fietz, D., Indumathy, S., Loveland, K. L., Hedger, M., Kliesch, S., Weidner, W., Bergmann, M., & Schuppe, H.-C. (2016) · Human Reproduction · doi:10.1093/humrep/dew211 · Cited by 114 · cited 1×
“…to infiltrating immune cells, increased transcript levels of pro-inflammatory cytokines, such as IL-1 β , IL-6 and TNF-α , anti-inflammatory cytokines (TGF-β 1), Th1-driven cytokines (IL-2 and IFN-γ ) and chemokines (CXCL-13, CXCL-10 and CCL-5) are found in patients with testicular tumors [20].”
BackgroundChemotherapy Broadens the Range of Tumor Antigens Seen by Cytotoxic CD8+ T Cells in Vivo
Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1307-4 · Cited by 105 · cited 1×
“With respect to specific chemotherapeutic agents, cisplatin can broaden the spectrum of tumor antigens in vivo, thereby facilitating the cytotoxic T-cell response [39].”
BackgroundSystemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90 · cited 2×
“Furthermore, although the levels of SII may serve as an independent prognostic indicator for progression-free survival (PFS) and overall survival (OS), when combined with PD-L1 expression on TILs, they can further stratify patients into three distinct prognostic groups [32].”
BackgroundSalvage high-dose chemotherapy for children with extragonadal germ-cell tumours
on behalf of the European Group for Blood and Marrow Transplantation Solid Tumours and Paediatric Disease Working Parties, De Giorgi, U., Rosti, G., Slavin, S., Yaniv, I., Harousseau, J. L., Ladenstein, R., Demirer, T., & Dini, G. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602724 · Cited by 85
Siska, P. J., Johnpulle, R. A. N., Zhou, A., Bordeaux, J., Kim, J. Y., Dabbas, B., Dakappagari, N., Rathmell, J. C., Rathmell, W. K., Morgans, A. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1305535 · Cited by 82 · cited 4×
“Siska et al. [27] also investigated the significance of the PD-1/PD-L1 signaling pathway in the immune escape of testicular cancer.”
BackgroundInfluentialDe Giorgi, U., Rosti, G., Aieta, M., Testore, F., Burattini, L., Fornarini, G., Naglieri, E., Lo Re, G., Zumaglini, F., & Marangolo, M. (2006) · European Urology · doi:10.1016/j.eururo.2006.05.011 · Cited by 81 · cited 1×
“In this setting, there is an ongoing effort to utilize novel treatment strategies that might result in improved clinical outcomes at a cost of fewer or/and less significant long term adverse events compared to platinum-based chemotherapy [9–12].”
BackgroundPhase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81 · cited 1×
“The primary endpoint of 12-week progression-free survival was not met, while the median PFS was 0.9 months and median OS was 2.7 months [52].”
BackgroundInfluentialFankhauser, C. D., Sander, S., Roth, L., Gross, O., Eberli, D., Sulser, T., Seifert, B., Beyer, J., & Hermanns, T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.467 · Cited by 80 · cited 1×
“SII and the other systemic inflammatory markers were characterized as independent prognostic predictors for OS in addition to the IGCCCG risk group classification [33].”
MethodChovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Svetlovska, D., Kalavska, K., Rejlekova, K., Spanik, S., Kajo, K., Babal, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15585 · Cited by 79 · cited 2×
“…system leading to disease dissemination is linked to reduced PD-L1 expression on TILs is further supported by a notable association between decreased PD-L1 expression in TILs and the presence of high-risk disease as defined by the International Germ Cell Cancer Collaborative Group (IGCCCG) [26].”
BackgroundFigueroa, J. A., Reidy, A., Mirandola, L., Trotter, K., Suvorava, N., Figueroa, A., Konala, V., Aulakh, A., Littlefield, L., Grizzi, F., et al. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1018419 · Cited by 78 · cited 1×
“Additionally, CAR-T-cell therapy can mitigate the off-target toxicities associated with low antigen affinity in traditional TCRs [64].”
BackgroundNecchi, A., Giannatempo, P., Raggi, D., Mariani, L., Colecchia, M., Farè, E., Monopoli, F., Calareso, G., Ali, S. M., Ross, J. S., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.010 · Cited by 78 · cited 2×
“In the arm where the combination of two ICIs was administered, one patient achieved partial response in multiple lung metastases, while another one had stable disease with improvement in serological markers [53].”
Recent advances in management of patients with platinum‐refractory testicular germ cell tumors
Kollmannsberger, C., Nichols, C., & Bokemeyer, C. (2006) · Cancer · doi:10.1002/cncr.21742 · Cited by 77 · cited 1×
“These approaches aim to provide a potential solution for patients who have limited options and are facing more challenging circumstances in their cancer management [4–8].”
BackgroundZhang, X., Wang, Y., A, G., Qu, C., & Chen, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721030 · Cited by 76 · cited 1×
“For example, high PARP1 expression in TGCTs, among other tumor types, is associated with CD8+ T-cell infiltration [72].”
BackgroundZschäbitz, S., Lasitschka, F., Hadaschik, B., Hofheinz, R.-D., Jentsch-Ullrich, K., Grüner, M., Jäger, D., & Grüllich, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.033 · Cited by 75 · cited 1×
“Two patients achieved long-term tumor response and this was associated with high PD-L1 expression levels [47].”
BackgroundThe Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers
Kozlova, N., Grossman, J. E., Iwanicki, M. P., & Muranen, T. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.01.001 · Cited by 73
De Giorgi, U., Demirer, T., Wandt, H., Taverna, C., Siegert, W., Bornhauser, M., Kozak, T., Papiani, G., Ballardini, M., & Rosti, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi017 · Cited by 69 · cited 1×
“These approaches aim to provide a potential solution for patients who have limited options and are facing more challenging circumstances in their cancer management [4–8].”
BackgroundLobo, J., Rodrigues, Â., Guimarães, R., Cantante, M., Lopes, P., Maurício, J., Oliveira, J., Jerónimo, C., & Henrique, R. (2019) · Cancers · doi:10.3390/cancers11101535 · Cited by 69 · cited 2×
“When jointly assessed, the level of PD-L1 expression displays no significant differences between seminomas and non-seminomas, although it is more abundant in choriocarcinomas than teratomas [29].”
BackgroundAnticancer drug delivery with nanoparticles.
(2006) · PubMed · Cited by 68
Feldman, D. R., Patil, S., Trinos, M. J., Carousso, M., Ginsberg, M. S., Sheinfeld, J., Bajorin, D. F., Bosl, G. J., & Motzer, R. J. (2012) · Cancer · doi:10.1002/cncr.26375 · Cited by 68
Infertility with Testicular Cancer
Ostrowski, K. A., & Walsh, T. J. (2015) · Urologic Clinics of North America · doi:10.1016/j.ucl.2015.05.003 · Cited by 61 · cited 1×
“In this setting, there is an ongoing effort to utilize novel treatment strategies that might result in improved clinical outcomes at a cost of fewer or/and less significant long term adverse events compared to platinum-based chemotherapy [9–12].”
BackgroundEngineered T cells for pancreatic cancer treatment
Katari, U. L., Keirnan, J. M., Worth, A. C., Hodges, S. E., Leen, A. M., Fisher, W. E., & Vera, J. F. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00344.x · Cited by 61 · cited 1×
“Furthermore, by displaying T-cell lytic properties it has the ability to directly kill target cells [65].”
BackgroundDel Giudice, F., Kasman, A. M., De Berardinis, E., Busetto, G. M., Belladelli, F., & Eisenberg, M. L. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.04.042 · Cited by 61 · cited 1×
“Interestingly, a systematic review and meta-analysis of population-based retrospective cohort studies in men with testicular cancer reported an association between male infertility and a subsequent 2-fold risk of developing testicular cancer [79].”
BackgroundAlbany, C., Einhorn, L., Garbo, L., Boyd, T., Josephson, N., & Feldman, D. R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0544 · Cited by 51 · cited 1×
“One patient exhibited a sustained complete response while the other had a partial response [54].”
BackgroundNair, R. K., & Westin, J. R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_10 · Cited by 51 · cited 1×
“…antibody fragment (scFV) known as the antigen-binding domain, located at the outer end, a hinge region that connects the scFV to the transmembrane region, and an intracellular region that contains the signal transduction portion of the TCR, along with one or two costimulatory domains [62].”
BackgroundMolecular and epigenetic pathogenesis of germ cell tumors
Müller, M. R., Skowron, M. A., Albers, P., & Nettersheim, D. (2021) · Asian Journal of Urology · doi:10.1016/j.ajur.2020.05.009 · Cited by 50 · cited 1×
“In TGCTs, the relationship between malignant cells and the surrounding tumor microenvironment (TME) seems to play an important role in the disruption of this balance [16–19].”
BackgroundSecondary malignant neoplasms in testicular cancer survivors
Curreri, S. A., Fung, C., & Beard, C. J. (2015) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.002 · Cited by 44
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
Tsimberidou, A.-M., Vo, H. H., Subbiah, V., Janku, F., Piha-Paul, S., Yilmaz, B., Gong, J., Naqvi, M. F., Tu, S.-M., Campbell, M., et al. (2021) · The Oncologist · doi:10.1002/onco.13682 · Cited by 43 · cited 1×
“The median progression-free survival was 2.4 months, while the median overall survival was 10.6 months [51].”
BackgroundInfluentialLearning from the “tsunami” of immune checkpoint inhibitors in 2015
Kourie, H. R., Awada, G., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.017 · Cited by 42 · cited 1×
“Several studies have evaluated the use of ICIs that target the PD-1/PD-L1 Cancers 2024 , 16 , 428 6 of 14 axis in different tumor types, showing a major biological effect on the reactivation of T cells and tumor specific T cells against cancer cells [46].”
BackgroundChi, E. A., & Schweizer, M. T. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.04.005 · Cited by 37 · cited 2×
“Moreover, a durable response to nivolumab was described in a patient with poor risk metastatic choriocarcinoma in a case report by Chi et al. [48].”
BackgroundA Systematic Pan-Cancer Analysis of CASP3 as a Potential Target for Immunotherapy
Zhou, Z., Xu, S., Jiang, L., Tan, Z., & Wang, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.776808 · Cited by 36 · cited 1×
“Besides this role, recent TCGA pan-cancer data revealed a low methylation status of the corresponding gene in TGCTs, which was associated with tumor mutational burden and microsatellite instability, thus indirectly providing a link between CASP3 expression and response to immunotherapy [73].”
BackgroundBo, H., Zhu, F., Liu, Z., Deng, Q., Liu, G., Li, R., Zhu, W., Tan, Y., Liu, G., Fan, J., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00588-9 · Cited by 35 · cited 2×
“A novel 150 immune-gene expression signature, named TIMEAS (tumor immune microenvironment activation status), was developed based on TCGA data from TGCTs [74].”
BackgroundMethodImamoglu, G. I., Eren, T., Baylan, B., & Karacın, C. (2019) · Urologia Internationalis · doi:10.1159/000502658 · Cited by 28 · cited 1×
“Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31–35].”
BackgroundLobo, J., Constâncio, V., Leite-Silva, P., Guimarães, R., Cantante, M., Braga, I., Maurício, J., Looijenga, L. H. J., Henrique, R., & Jerónimo, C. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01048-y · Cited by 28 · cited 2×
“…consists of a major pathway of resistance in various tumor types, including TGCTs, particularly in the cisplatin-resistant setting which is characterized by the enrichment of differentially hypermethylated promoters on pathways related to the regulation of the immune microenvironment [77].”
BackgroundMethodSanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002446 · Cited by 28 · cited 1×
“…antibody ipilimumab, examined 27 patients reporting a tolerable profile at a recommended phase 2 dose of 10 mg/kg as well as preliminary efficacy with an overall response rate of 19%, including one testicular cancer patient who had a partial response which was durable for >12 months [78].”
BackgroundJennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27 · cited 1×
“Peri-tumoral migration of these PD-1-positive infiltrating cells in testicular tissue containing GCN is facilitated by angiogenic signaling through the VEGFR2 receptor [25].”
BackgroundSadigh, S., Farahani, S. J., Shah, A., Vaughn, D., & Lal, P. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz184 · Cited by 26 · cited 1×
“In this context, seminomas exhibit a higher presence of PD-L1+ TAMs within the tumor compared to non-seminoma TGCTs [30].”
BackgroundGuo, J., Wang, S., Jiang, Z., Tang, L., Liu, Z., Cao, J., Hu, Z., Chen, X., Luo, Y., & Bo, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859730 · Cited by 25 · cited 1×
“…(RFPL3S) is another putative biomarker of immunotherapy efficacy, as it was positively associated with the infiltration of immune-activating B cells, CD8+ T cells, cytotoxic T cells, and natural killer cells, and was negatively associated with immunosuppressive cells, including Th17 and Th2 [75].”
BackgroundMackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.035 · Cited by 25 · cited 2×
“…an ongoing clinical trial testing a CAR-T cell (BNT211) against CLDN6 as monotherapy and in combination with CLDN6-encoding CAR-T-cell-amplifying RNA vaccine (CARVac) in patients with CLDN6-positive solid tumors was launched, also enrolling patients with refractory or multiple-relapsed GCTs [67].”
BackgroundLoh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23 · cited 1×
“However, the patient’s tumor progressed rapidly soon after starting immunotherapy, leading to the early discontinuation of the ICI [49].”
BackgroundSkowron, M. A., Eul, K., Stephan, A., Ludwig, G. F., Wakileh, G. A., Bister, A., Söhngen, C., Raba, K., Petzsch, P., Poschmann, G., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13282 · Cited by 20 · cited 1×
“Most importantly, cisplatin sensitivity was found to be decreased in these patients [21].”
BackgroundGanguli, N., Kumari, P., Dash, S., & Samanta, D. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.07.058 · Cited by 20 · cited 1×
“Interestingly, preclinical evidence suggests an interplay and direct interaction between Nectin-4 and TIGIT as well as an upregulation of TIGIT and other immune-suppressive signals in metastatic compared to primary sites [69,70].”
BackgroundCursano, M. C., Kopf, B., Scarpi, E., Menna, C., Casadei, C., Schepisi, G., Lolli, C., Altavilla, A., Gallà, V., Santini, D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01325 · Cited by 19 · cited 1×
“Various studies reported that there were significant differences between neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and systemic inflammation index (SII), in early and advanced stage GCTs [31–35].”
BackgroundSöhngen, C., Thomas, D. J., Skowron, M. A., Bremmer, F., Eckstein, M., Stefanski, A., Driessen, M. D., Wakileh, G. A., Stühler, K., Altevogt, P., et al. (2023) · The FEBS Journal · doi:10.1111/febs.16880 · Cited by 19 · cited 1×
“CD24 is a membrane protein that has also been proposed as a target for NK-CAR immunotherapy by virtue of its SOX2-mediated transactivation in embryonal carcinoma cells enabling the induction of cell death in CD24-positive cells in vitro [68].”
BackgroundNecchi, A., Magazzu, D., Anichini, A., Raggi, D., Giannatempo, P., Nicolai, N., Colecchia, M., Paolini, B., Coradeschi, E., Tassi, E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.2_suppl.480 · Cited by 17 · cited 1×
“Among them, 11.1% of the patients had progression-free survival (PFS) of 3 months, while 85.7% of the patients achieved 6-month overall survival (OS)) [55].”
BackgroundInfluentialChimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
Martino, M., Naso, V., Loteta, B., Canale, F. A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113332 · Cited by 17 · cited 1×
“This is primarily due to various obstacles, particularly including intra-tumor heterogeneity and pro-tumoral activity mediated by TME [66].”
BackgroundPęksa, R., Kunc, M., Popęda, M., Piątek, M., Bieńkowski, M., Żok, J., Starzyńska, A., Perdyan, A., Sowa, M., Duchnowska, R., et al. (2021) · Cancers · doi:10.3390/cancers13081750 · Cited by 16 · cited 2×
“Mixed tumors, teratomas or areas containing teratomas displayed very weak or no expression of immune checkpoints, with PD-L1 levels below 5% and VISTA cell positivity below 5% [28].”
BackgroundPhase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01134-1 · Cited by 16 · cited 2×
“Recently, a phase II one arm study enrolling 18 patients investigated brentuximab vedotin in CD30-positive and CD30-negative/unknown patients [56].”
BackgroundInfluentialThe Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer
Ribnikar, D., Stukalin, I., Bedard, P. L., Hamilton, R. J., Jewett, M., Warde, P., Chung, P., Anson-Cartwright, L., Templeton, A. J., Amir, E., et al. (2020) · Current Oncology · doi:10.3390/curroncol28010014 · Cited by 15 · cited 1×
“However, other studies question the independent prognostic value of elevated NLR demonstrating a lack of significant association with shorter PFS and OS independently of the IGCCCG risk groups [34].”
BackgroundRole of Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors
Nguyen, C. T., & Stephenson, A. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.03.002 · Cited by 14 · cited 1×
“Metastatic GCTs represent the model of curable neoplasm since the combination of cisplatin-based chemotherapy and Cancers 2024 , 16 , 428 2 of 14 surgical removal of any residual retroperitoneal mass may achieve a 10-year disease-free survival of up to 95% [2].”
BackgroundGiorgi, U. D., Rosti, G., Salvioni, R., Papiani, G., Ballardini, M., Pizzocaro, G., & Marangolo, M. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.030 · Cited by 14
Milia-Argeiti, E., Mourah, S., Vallée, B., Huet, E., Karamanos, N. K., Theocharis, A. D., & Menashi, S. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.026 · Cited by 14
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology
Lazar, V., Zhang, B., Magidi, S., Le Tourneau, C., Raymond, E., Ducreux, M., Bresson, C., Raynaud, J., Wunder, F., Onn, A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156382 · Cited by 14 · cited 1×
“Interestingly, preclinical evidence suggests an interplay and direct interaction between Nectin-4 and TIGIT as well as an upregulation of TIGIT and other immune-suppressive signals in metastatic compared to primary sites [69,70].”
BackgroundExpression of the immune checkpoint receptor TIGIT in seminoma
Hinsch, A., Blessin, N., Simon, R., Kluth, M., Fischer, K., Hube‑Magg, C., Li, W., Makrypidi‑Fraune, G., Wellge, B., Mandelkow, T., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10428 · Cited by 12 · cited 1×
“Notably, TIGIT (T-cell immunoreceptor with Ig and ITIM domains) was found to be significantly overexpressed [57].”
BackgroundMeng, J., Gao, J., Li, X., Gao, R., Lu, X., Zhou, J., Yan, F., Wang, H., Liu, Y., Hao, Z., et al. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00781-1 · Cited by 9 · cited 2×
“[76].”
BackgroundPantuck, M., Palaskas, N., & Drakaki, A. (2018) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2018.08.001 · Cited by 7 · cited 1×
“As its activity relies on the interaction between the cell surface and antigens, CAR-T-cell therapy is independent of major histocompatibility complex (MHC) restriction, consisting of a viable therapeutic strategy in tumors with limited MHC expression [63].”
BackgroundChovanec, M., Mego, M., Cholujova, D., Gronesova, P., Miskovska, V., Sycova-Mila, Z., Usakova, V., Svetlovska, D., Bujdak, P., Spanik, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e15552 · Cited by 6
Al-Hogbani, M., Duguay, J., Wagner, D.-C., Haferkamp, A., Joubert, P., Frees, S., Rendon, R., Power, N., Périgny, M., & Toren, P. (2021) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.02.014 · Cited by 5 · cited 1×
“…CPS scores were significantly higher in metastatic compared to primary testicular tumors and, secondly, predominantly or pure seminoma patients had a significant increase in CPS post-chemotherapy, suggesting that this subgroup might be a reasonable population for future immunotherapy trials [45].”
ResultZhao, J., Qin, L., He, G., Xie, T., Hu, G., Wang, F., Zhong, H., Zhu, J., & Xu, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6605 · Cited by 3 · cited 1×
“…with GPC3144-152 showed an induction of tumor-specific CD8+ T cells secreting high levels of IFN-γ and granzyme B and led to growth inhibition in yolk sac tumors [71]. molecules that may directly or indirectly be implicated in antitumor immune response could be exploited for therapeutic targeting.”
Background
Cited by
Udvorková, N., Fekiačová, A., Majtánová, K., Mego, M., & Kučerová, L. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00200.2024 · Cited by 8
Mehr, F. K., Emtiazi, N., & Zolfi, E. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103169 · Cited by 6
Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors
Sperber, L., von Brandenstein, M., Kessler, C., Heidenreich, J., Storz, E., Pfister, D. G., Paffenholz, P., Tolkach, Y., Bernhardt, M., Wirtz, R., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06325-4 · Cited by 3
“…often seen in CC. SG exhibits strong cytotoxicity in TROP2-pos-itive, chemotherapy-resistant GCT cells; however, its clini - cal effectiveness still needs to be confirmed. due to the low tumor mutational burden and the lack of effective biomarker-based patient selection (Evmorfopoulos et al. 2024).”
Zhao, H., Liu, W., Xu, H., Wang, L., Chen, Z., Sun, Y., & Wang, L. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04374-3 · Cited by 3
“This enrichment aligns with the distinct immunobi-ology of these malignancies: TGCTs are characterized by intense lymphocytic infiltration[29], THYM is intrinsically linked to T-cell development[30], and BRCA is shaped by continuous immunosurveillance mechanisms [31].”
Decoding testicular germ cell tumors: integrating risk, biology, and biomarkers into future care
Bowling, G. C., Lacson, J. C. A., Almeida, A. A., Rhee, J., Chesnut, G. T., Nichols, C. R., & Kern, S. Q. (2026) · Gene · doi:10.1016/j.gene.2026.150044 · Cited by 2
Metadata
- Authors
- Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J.
- Affiliations
- University of Thessaly (GR)
- Aberdeen Royal Infirmary (GB)
- Corresponding author
- Vlachostergios, Panagiotis J.
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-01-19
- Volume
- 16
- Issue
- 2
- Pages
- 428
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC10814346
- OpenAlex
- W4391029848
- Cited by
- 11
- References
- 83
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- testicular germ cell tumors, platinum-refractory disease, immune microenvironment, immune checkpoint inhibitors, PD-1/PD-L1 axis, anti-CTLA-4 monoclonal antibody, antibody-drug conjugates, cancer vaccines, tyrosine kinase inhibitors, CAR T-cell therapy, immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
